MCM
VKTX icon

MAI Capital Management’s Viking Therapeutics VKTX Stock Holding History

MAI Capital Management’s Portfolio VKTX Stock Details VKTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$34.7K Buy
1,067
+277
+35% +$8.9K ﹤0.01% 2472
2025
Q4 		$27.8K Hold
790
– – ﹤0.01% 2341
2025
Q3 		$20.8K Sell
790
-81
-9% -$2.42K ﹤0.01% 2386
2025
Q2 		$23.1K Buy
871
+349
+67% +$9.19K ﹤0.01% 2279
2025
Q1 		$12.6K Buy
522
+200
+62% +$6.32K ﹤0.01% 2396
2024
Q4 		$13K Buy
+322
New +$18.4K ﹤0.01% 2400

Other funds holding VKTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

MAI Capital Management's VKTX Position: Q1 2026 in Review

MAI Capital Management increased its Viking Therapeutics (VKTX) stake by 35% in Q1 2026, buying an estimated $8.9K and bringing the position to 1,067 shares worth $34.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2472.

MAI Capital Management first reported a position in VKTX in Q4 2024 and has held it in 6 quarters since. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

  • MAI Capital Management held 1,067 shares of Viking Therapeutics worth $34.7K as of Q1 2026.
  • MAI Capital Management bought 277 Viking Therapeutics shares in Q1 2026, an estimated $8.9K.
  • Viking Therapeutics made up ﹤0.01% of MAI Capital Management's portfolio in Q1 2026, its #2472 holding.
  • MAI Capital Management first reported a position in Viking Therapeutics in Q4 2024 and has held it in 6 quarters since.
  • 410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on MAI Capital Management's 13F filing for Q1 2026, filed 15 May 2026.